Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1915 results
April 2026
-
Story
New long term social impact and sustainability targets
Novartis has announced new long-term Social Impact & Sustainability (SI&S) targets and goals, reinforcing our commitment to go beyond breakthroughs to maximize the impact of our medicines to support inclusive, resilient healthcare systems worldwide.
-
Story Access to Healthcare
Working with communities to close gaps in heart disease and cancer care
Our innovations matter only when they reach the people who need them. Yet millions live with heart disease or cancer without knowing it or have limited access to care – especially those in low-income, rural or other hard-to-reach communities.
-
Press release
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population healthScales program footprint from 11 countries to more than 30 by 2030,…
March 2026
-
Story Patient Perspectives
Managing Quality of Life with CML
How shared decision-making can support living well from the start with chronic myeloid leukemia
-
Press release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study140.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years1Fabhalta… -
Press release
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated… -
Press release
Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026
New Rhapsido® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presentedLong-term Cosentyx® data build on extensive body of evidence… -
Press release
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
Proposed acquisition supports the Novartis oncology strategy in hormone receptor positive, human epidermal growth factor receptor two-negative (HR+/HER2-) breast cancer The lead asset, SNV4818,… -
Story People and Culture
Building the Future: Novartis Innovation Lab - AI, Game Studio, XR & Emerging Tech
The leaders behind the Novartis Innovation Lab share how they are leveraging emerging technologies to win for patients.
-
Press release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring… -
Story From Our Labs
Bringing proteins together to take cancer apart
A Q&A with Jake Haling, Head of Oncology Drug Discovery in San Diego, on induced proximity and how it could open new paths to treat cancer.
-
Story People and Culture
Turning personal experience into purpose-driven careers
What drives someone to dedicate their career to reimagining medicine? Three women at Novartis share their deeply personal and unique stories.